Why the study?
Is the Autocapture algorithm safe and functional in patients with congenital heart disease receiving transvenous or epicardial pacemakers?
Is the Autocapture algorithm safe and functional in patients with congenital heart disease receiving transvenous or epicardial pacemakers?
The Autocapture algorithm is safe and effective in congenital heart disease patients with transvenous leads, but its reliability with epicardial leads is limited and requires individual verification.
May support Autocapture in transvenous systems for congenital heart disease; leaves open epicardial reliability and requires prospective validation.
AIMS: The purpose of this study was to reevaluate whether St Jude Medical's Autocapture algorithm (AC) with beat-to-beat capture confirmation, automatic pacing threshold determination and output adjustment can be applied to paced patients with congenital heart disease (CHD). METHODS AND RESULTS: 30 patients with CHD received a transvenous (group A: n=22) or epicardial (group B: n=8) single (n=7) or dual chamber (n=23) AC pacemaker for antibradycardia pacing. As a safe AC function is ensured only if a sufficient evoked response (ER) and a low lead polarization amplitude (LPA) are present, these parameters were reevaluated from 112 follow-up studies with respect to AC-function. In all but one transvenous system AC correctly functioned. AC was recommended in 5/8 patients with epicardial leads but correct AC function was preserved in only 3 patients. CONCLUSION: These data suggest that the application of the AC algorithm is safe in patients with CHD when transvenous leads are used. Whether appropriate AC function is possible with epicardial leads needs individual verification.
No takes yet. Share an insight, caveat, or question.
J. Nürnberg (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: